
COYA Stock Forecast & Price Target
COYA Analyst Ratings
Bulls say
Coya Therapeutics is a clinical-stage biotechnology company with a positive outlook, as shown by their promising clinical programs and market opportunities for their proprietary therapies targeting Tregs. Despite competition and risks in the biotech industry, Coya Therapeutics has strong partnerships and ongoing pipeline expansion strategies, backed by solid intellectual property and orphan drug designations. With a current valuation and 12-month price target of $14 per share based on future revenue projections, Coya Therapeutics has solid potential for growth, especially considering its recent publication reinforcing the therapeutic potential of its product COYA 302 for frontotemporal dementia.
Bears say
Coya Therapeutics is a clinical-stage biotechnology company that is at risk of facing competition in the intense biotechnology and pharmaceutical industry. Their current product candidate pipeline shows potential, but with a lack of revenue and increasing cash burn, there is a strong likelihood that the company will need to raise additional capital in the future. Additionally, while initial clinical data supports efficacy and safety of their product, there is a risk that regulators may not approve it for the requested indications.
This aggregate rating is based on analysts' research of Coya Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
COYA Analyst Forecast & Price Prediction
Start investing in COYA
Order type
Buy in
Order amount
Est. shares
0 shares